中國醫療集團(08225.HK)前三季度收入約5582.9元 同比上升約8.5%
格隆匯11月11日丨中國醫療集團(08225.HK)發佈公吿,截至2021年9月30日止9個月,營業收入約人民幣5582.9元,較2020年同期營業收入上升約8.5%。集團錄得本期除税前利潤約人民幣3105.9萬元,較2020年同期除税前利潤下降約16.1%。每股盈利(基本)約為人民幣2.59仙,較2020年同期下降約21.5%。董事會建議不派發截至2021年9月30日止九個月股息。
隨着中國醫藥企業商業模式的變化,中國醫療集團承擔起了以CRO以及CSO模式組合替代傳統CSO模式的責任。集團不斷在增強市場推廣能力及拓展市場網路方面做出投資,以中國醫療集團及子品牌喜恩萬全、拜敏萬全、健壽萬全、悦戒煙在本土市場推出全價值鏈的專注治療領域產品品類增值的業務模式;董事會也將按穩建的原則審核評估可能進行的專案或投資,務求提升本集團業務表現及本公司股東回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.